Louis Brenner

Dr. Lou Brenner is the president and chief operating officer of Allena Pharmaceuticals (NASDAQ:ALNA). Lou has more than a decade of industry leadership experience in pharmaceutical development strategy, regulatory affairs, business development and marketing with a focus on novel therapies for kidney patients. He has lead successful drug development programs including the Phase 3 program for Feraheme® (ferumoxytol) injection in patients with chronic kidney disease (CKD) at AMAG Pharmaceuticals (NASDAQ:AMAG), the global Phase 3 trial of TYMLOSTM (abaloparatide) for the treatment of postmenopausal osteoporosis at Radius Health (NASDAQ:RDUS), and global strategic planning for Renvela® (sevelamer carbonate) in patients with end stage renal disease at Genzyme.

Lou earned a B.S. from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School. He completed his residency in internal medicine at Brigham and Women’s Hospital (BWH) and his fellowship in nephrology at BWH and Massachusetts General Hospital. Lou currently holds a clinical appointment and cares for patients with kidney diseases at BWH. He serves on the board of Yale Boston and was formerly a board member at PLC Medical Systems and Chairman of the Board of the National Kidney Foundation’s New England subsidiary.